N. Iqbal
Oncology · 1 papers · 2014
A researcher in the Science corpus: 1 paper; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 20 citations into it
- Radiology, Nuclear Medicine and Imaging — 8 citations into it
Whom N. Iqbal trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from N. Iqbal's perspective
Ordered by how strongly the researchers N. Iqbal trusts endorse each paper. Same corpus, a different order for every researcher.
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. (Annals of Oncology)
- Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. (Journal of the National Cancer Institute)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer. (New England Journal of Medicine)
- EGF–ERBB signalling: towards the systems level (Nature reviews. Molecular cell biology)
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (New England Journal of Medicine)
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (New England Journal of Medicine)
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (New England Journal of Medicine)
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (Oncogene)
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. (Annals of Oncology)